Differences in the prognosis according to the periods of diagnosis in ulcerative colitis

Hyun B.eom Chae, Yoon S.uk Jung, Dong I.l. Park, Chang K.yun Lee, Kyu C.han Huh, Jeong E.un Shin, Jae H.ak Kim, You S.un Kim, Yunho Jung, Sung A.e. Jung, Hyun J.u. Song, Hyun J.oo Jang, Sung N.oh Hong, Young H.o. Kim

Research output: Contribution to journalArticlepeer-review


BACKGROUND/AIMS: Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC. The aim of this study was to investigate the differences of medication use and prognosis in UC patients according to the periods of diagnosis.

METHODS: From 1987 to 2012, a total of 1,422 patients with UC were retrospectively reviewed in 12 hospitals. The study population was divided into two groups according to the periods of diagnosis as follows; group A: 1987-2005, group B: 2006-2012. Analyzed variables were compared by using chi-square test and logistic regression analysis.

RESULTS: Mean age of the subjects was 42.2 years, and the mean follow-up period was 4.7 years. In univariate analysis, the use of infliximab in group B was significantly higher than group A (4.5% vs. 7.6%, p=0.016), and UC-related hospitalization (45.8% vs. 40.1%, p=0.031) and UC-related surgery (6.4% vs. 3.5%, p=0.010) in group B was significantly lower than that of group A. The use of oral steroid in surgery group was significantly higher than non-surgery group in multivariate analysis (OR 1.85, 95% CI 1.03-3.30, p=0.039).

CONCLUSIONS: Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Issue number2
StatePublished - 1 Aug 2014


Dive into the research topics of 'Differences in the prognosis according to the periods of diagnosis in ulcerative colitis'. Together they form a unique fingerprint.

Cite this